Athira Pharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $20,874 | $48,438 |
| Short-term investments | 4,352 | 2,837 |
| Prepaid expenses and other current assets | 1,799 | 3,566 |
| Total current assets | 27,025 | 54,841 |
| Restricted cash | 631 | 631 |
| Property and equipment, net | 1,715 | 2,444 |
| Operating lease right-of-use asset | 607 | 808 |
| Other long-term assets | 55 | 55 |
| Total assets | $30,033 | $58,779 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $266 | $319 |
| Accrued liabilities | 2,069 | 12,402 |
| Current operating lease liability | 452 | 414 |
| Total current liabilities | $2,787 | $13,135 |
| Operating lease liability, less current portion | 460 | 803 |
| Total liabilities | 3,247 | 13,938 |
| Stockholders' equity: | ||
| Common stock, $0.0001 par value; 90,000,000 shares authorized at September 30, 2025 and December 31, 2024, respectively; 3,943,887 and 3,904,049 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively (1) | 4 | 4 |
| Additional paid-in capital | 455,650 | 450,982 |
| Accumulated other comprehensive (loss) income | (2) | 1 |
| Accumulated deficit | (428,866) | (406,146) |
| Total stockholders' equity | 26,786 | 44,841 |
| Total liabilities and stockholders' equity | $30,033 | $58,779 |
(1) The Company effected a reverse stock split of its outstanding shares of common stock on September 17, 2025 where every ten shares of its common stock issued and outstanding was converted into one shareof common stock. Any fractional post-split shares as a result of the reverse stock split were rounded down to the nearest whole post-split share. Stockholders of the Company previously authorized the Board of Directors to approve a reverse stock split at the Company's annual meeting on May 29, 2025. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the reverse stock split on a retroactive basis in all periods presented.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.